翰森製藥(03692.HK)公佈中期業績 純利大幅增長約111.5% 將持續加大在創新研發上的投入
格隆匯8月27日丨翰森製藥(03692.HK)公吿，截至2024年6月30日止六個月，集團錄得收入約人民幣65.06億元，較上年同期增長約44.2%；溢利約人民幣27.26億元，較上年同期增長約111.5%；集團創新藥與合作產品銷售收入約人民幣50.32億元，同比增長約80.6%，其佔總收入比重已達約77.4%。
截至2024年6月30日止六個月內，於中國提交正式專利申請二十一件，獲國內授權專利二十九件；海外專利正式申請四十九件，獲海外授權二十件。
於截至2024年6月30日止六個月內，集團正在進行的創新藥臨牀試驗超過五十項，分屬於超過三十個創新藥產品。
回顧期內首次獲批臨牀的重點創新藥包括：自研1類新藥HS-10501片(擬用於治療2型糖尿病和成人肥胖症)；自研1類新藥HS-10398膠囊(擬用於治療免疫球蛋白A腎病和膜性腎病)；自研1類新藥HS-10504片(擬用於治療晚期NSCLC)；與自荃信生物引入的HS-20137單抗(擬用於治療銀屑病等自免疫疾病)等。
成為全球領先的創新驅動型製藥企業是公司的企業願景，公司將持續加大在創新研發上的投入，把握不斷變化的外部機遇，加速研發成果的轉化，推進創新藥物和治療方案的快速上市，從而更好地滿足中國乃至全球患者未滿足的醫療需求。公司將堅定推進健康可持續發展，積極踐行企業社會責任，為股東、患者、社會等利益相關方創造更大價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
